Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) issued its quarterly earnings results on Friday. The company reported ($0.51) earnings per share for the quarter, Zacks reports. Cardio Diagnostics had a negative net margin of 36,950.00% and a negative return on equity of 78.82%. The company had revenue of $0.01 million during the quarter.
Cardio Diagnostics Stock Performance
Shares of CDIO stock opened at $1.79 on Friday. Cardio Diagnostics has a fifty-two week low of $0.97 and a fifty-two week high of $7.91. The stock has a 50 day simple moving average of $1.88 and a two-hundred day simple moving average of $2.14. The company has a market cap of $5.30 million, a P/E ratio of -0.61 and a beta of 2.27.
Institutional Inflows and Outflows
A hedge fund recently bought a new position in Cardio Diagnostics stock. Citadel Advisors LLC purchased a new position in Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 19,520 shares of the company’s stock, valued at approximately $79,000. Citadel Advisors LLC owned about 1.07% of Cardio Diagnostics as of its most recent SEC filing. 8.06% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
View Our Latest Analysis on Cardio Diagnostics
Cardio Diagnostics Company Profile
Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.
Read More
- Five stocks we like better than Cardio Diagnostics
- AI Cold War Catches Light: Federal Friction in the Server Rack
- 3 Stocks Whose Charts May Be Signaling the Next Big Move
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
Receive News & Ratings for Cardio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
